Index

Note: page numbers in italics refer to figures; those in bold to tables or boxes.

abacavir 686
acamprosate
alcohol dependence 397, 397, 402–403
re-starting after non-adherence 795
ACE inhibitors see angiotensin-converting enzyme inhibitors
acetaldehyde 753
acetiomophen, in dementia 564, 571
acetylcholinesterase (AChE) 529
inhibitors 529–543, 530–531
adverse effects 537–538, 539
Alzheimer's disease 529–543, 544, 576
clinical guidelines 544, 551, 551
combination therapy 536
delirium 675
dosing 535
drug interactions 223, 539–540, 541–542
efficacy 532–533, 534
Lewy body dementia 538, 550, 576, 717
mechanism of action 529
mild cognitive impairment 533, 537, 550
myasthenia gravis 564, 567
non-cognitive symptoms of dementia 535, 576
other dementias 550–551
Parkinson's disease 530, 576, 717
re-starting after non-adherence 795
stopping treatment 540–543
switching between 534
tolerability 536–537
vascular dementia 549
see also donepezil; galantamine;
rivastigmine
acetylcysteine (N-acetylcysteine)
autism spectrum disorders 505
obsessive compulsive disorder 364
refractory schizophrenia 163
acetyl-L-carnitine 754
activated partial thromboplastin time 805
acute intoxication see intoxication, acute
core kidney injury 647
acute disturbed behaviour 54–64
intoxication with street drugs 56, 450
rapid tranquillisation 54–59
acute mania see mania, acute
addictions 385–457
S-adenosyl-l-methionine 275
ADHD see attention deficit hyperactivity disorder
adherence, medication 787–793
assessment 732, 789
children and adolescents 486
enhancing 789–792
factors affecting 788
lithium therapy 206, 209
rates 787–789
re-starting medication after missed
doses 794–797, 795
schizophrenia 4, 27, 42, 787–788, 790
adolescents see children and adolescents
adverse drug reactions (ADR)
autism spectrum disorder 504
biochemical 798, 799–804
breasted infants 620, 622–630
children and adolescents 461
haematological 798, 805–807
hepatic impairment 636
HIV infection 680
learning disability 700
medication adherence and 788, 790
Narajan probability scale 811, 812
older people 525
psychiatric see psychiatric adverse effects
renal impairment 647
see also teratogenicity
affective disorders
caffeine consumption 762
non-psychotropics causing 808, 809, 810
stupor 107, 108, 109
see also bipolar disorder; depression;
mania
aging
pharmacodynamic changes 525
pharmacokinetic changes 526
see also older people
aggressive behaviour
autism spectrum disorders 506–508
benzodiazepine-associated 374, 381–383
carbamazepine 222
dementia see behavioural and
cognitive symptoms (BPSD) of
dementia
Huntington's disease 706
learning disabilities 701–702
lithium 207
non-psychotropics causing 809
valproate 215
see also acute disturbed behaviour
agitation

dementia see behavioural and psychological symptoms of dementia

non-psychotropics causing 808, 809, 810

rapid tranquillisation 54–57

tagomelatine

adverse effects 358

atral fibrillation 720

breast cardiac effects 326

depression 264

diabetes mellitus and 340

discontinuation 310, 312, 315, 318

driving ability 777

epilepsy 692

generalised anxiety disorder 360

hepatic impairment 639

hyperprolactinaemia and 337

hypomania 333, 333

minimum effective dose 262

older people 294, 295, 587

overdose 769

Parkinson's disease 715

renal impairment 651

sexual adverse effects 344

smoking status and 750

switching to/from 316, 318

agnanulocytosis

clozapine-chemotherapy combination 202

clozapine-induced 176, 179, 184–185, 197–201

psychotropics causing 806

see also neutropenia

AIDS see HIV infection/AIDS

akathisia

antipsychotic-induced 39, 91–92, 94–96

never-medicated schizophrenia 90

non-psychotropics causing 810

switching antipsychotics 150

treatment 92, 94, 95–96

D-alanine, refractory schizophrenia 163

alaine aminotransferase (ALT) 799

albumin, plasma 799

albumin:creatinine ratio (ACR) 645, 646

alcohol 387

bariatric surgery and 727

driving and 777

drug interactions 451–452, 753–757, 754, 755

metabolism 753, 753

methadone interaction 410, 412

post-mortem blood samples 742, 743

units 387

alcohol consumption

pregnancy 400

recommendations 387

alcohol dehydrogenase (ADH) 753, 753

drugs inhibiting 754

alcohol dependence/misuse 387–404

assessment 387–388

brief structured intervention 387–388

children and adolescents 400–401

co-morbid mental health disorders 401–403

concurrent drug use disorders 401

drug interactions 753–756, 754, 755

mild, assisted withdrawal 392, 393

moderate, assisted withdrawal 392, 393, 399

NICE guideline 387, 397, 398, 399

older adults 401

psychotropic drug choice 756

relapse prevention 397–400

severe, assisted withdrawal 392, 394, 394

treatment see alcohol withdrawal

Wernicke's encephalopathy 395–396

alcohol intoxication

drug interactions 754, 754, 756

rapid tranquillisation 56

Alcohol Use Disorders Identification Test (AUDIT) 388

alcohol withdrawal 388–396

carbamazepine 222

children and adolescents 400–401

clinical features 388–389

community setting 390, 393

complications 388–389

fixed dose reduction regimen 393–394

front-loading regimen 393

inpatient/residential settings 390, 393, 394–395

older adults 401

pharmacologically assisted (detoxification) 390–395, 392

pregnancy 400

somatic complaints, and remedies 396, 396

symptom-triggered regimen 394, 394–395

variable dose reduction 393

Wernicke's encephalopathy 395–396

aldehyde dehydrogenase 753, 753

drugs inhibiting 754

alfuzosin 561

alkaline phosphatase 799

allopurinol 162, 237

a2-adrenergic agonists

ADHD 497

autism spectrum disorders 506

PTSD in young people 492, 493

tic disorders 513

see also clonidine; guanfacine

alpha-blockers

PTSD in young people 492, 493

urinary retention in dementia 561, 568

alpha-lipoic acid 100

alprofostil 144, 145

alverine 563

Alzheimer's disease (AD) 529–549

antipsychotic-associated pneumonia 148

atrial fibrillation and 720

BAP guidance 531, 551

cognitive enhancers 529–543, 530–531

deficiency 577–578

driving regulations 776

efficacy of drug treatment 532–534

NICE guidance 543, 544

non-cognitive symptoms see behavioural and psychological symptoms (BPSD) of dementia

novel treatments 548–549

other treatments 543–548

quantifying drug effects 534

stopping treatment 540–543, 543

see also dementia

Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog) 532, 534

amantadine

antipsychotic-induced weight gain 100

Huntington's disease 705

hyperprolactinaemia 139

multiple sclerosis 711–712

psychiatric adverse effects 810

refractory depression 274

dehumanisation 144, 145, 343

American Academy of Child and Adolescent Psychiatry (AACAP) 463, 480, 491

amfebutamine see bupropion

amfetamines

autism spectrum disorders 506

depression 285, 286–287

drug interactions 451–452

epilepsy 693

misuse 439–440, 455

psychosis induced by 440

see also dexamfetamine; lisdexamfetamine

Amiket (amitriptyline + ketamine cream) 300

amisulpride

adverse effects 39

alcohol misusers 756

bipolar disorder 226

breastfeeding 625

clozapine-induced hypersalivation 189

delirium 674

dementia 572, 574, 575

depression 278

diabetes and 124–125

epilepsy 692

equivalent dose 15

hepatic impairment 637, 641

Huntington's disease 706

maximum licensed dose 12

minimum effective dose 9

monitoring physical health 37, 38

negative symptoms 32

older people 588

overdose 771
plasma level monitoring 732–734, 733
pneumonia risk 148
recreational schizophrenia 159, 162, 163, 164
relative efficacy 5
renal impairment 649
sexual adverse effects 143
switching to 51
weight gain risk 97
amitriptyline
adverse effects 358
autism spectrum disorders 508
breastfeeding 624
buccal 299
children and adolescents 464–465
clozapine-induced hypersalivation 189
discontinuation symptoms 311
effectiveness 257
gel 300, 302
intramuscular 302
intravenous 299, 302
and ketamine cream 300
Parkinson’s disease 715
plasma level monitoring 734
post-mortem blood concentrations 743
post-stroke depression 290
PTSD 363
rectal 301, 303
renal impairment 651
surgery-related risk 783
ammonia, serum 799
amnesia, alcohol-induced 755
amoxapine, epilepsy 692
amphetamines
anaesthetic agents 781
analgesic agents
dementia 564–565, 568, 571
naltrexone-treated patients 398, 426
opioid-dependent patients 420, 426
psychiatric adverse effects 808
angiotensin II antagonists
cognitive effects 566
lithium interactions 210, 211
angiotensin-converting enzyme (ACE) inhibitors
lithium interactions 210, 211
psychiatric adverse effects 808
ANNERS (Antipsychotic Non-Neurological Side-Effects Rating Scale) 5–6
anorexia nervosa 667–669, 670
Antabuse see disulfiram
anti-androgens, obsessive-compulsive disorder 365
antiarhythmics, QT prolongation 115
antibiotics
dementia 566, 567
psychiatric adverse effects 808
QT prolongation 115
anticholinergic agents
antidepressant discontinuation symptoms 312
bronchodilators 563–564
with depot antipsychotics 69
extrapyramidal symptoms 92, 95
hypersalivation 189, 190, 564
Parkinson’s disease 716, 717
safety in dementia 557–564, 561, 567, 568
street drug interactions 452
urinary incontinence 557–561, 562, 568
anticholinergic effect on cognition (AEC) scores 557, 558–560, 561
anticholinergic effects
antidepressants 294–295, 296, 321, 358–359
antipsychotics 39, 142
anticholinesterases see acetylcholinesterase (AChE) inhibitors
anticoagulation, SSRIs and 291
藿芍氏症 5–6
relative efficacy 5
refractory schizophrenia 267–273
sexual adverse effects 134–135
autism spectrum disorders 505, 508
cognitive effects 566
course of action 257–258
drug interactions 223, 259, 321–324
eating disorders 668, 669
ECT interactions 281
epilepsy 691, 692
haematological effects 805–807
hepatic impairment 638, 639, 641
HIV infection 680–681
Huntington’s disease 706
hyperprolactinaemia and 337, 337–339
hypotensive effects 323, 333–336
intra-gastric (IG) 298
intra-jejunal (IJ) 298
intra-gastric (IG) 298
intra-muscular (IM) 298–302
intravenous (IV) 299–300
learning disabilities 701
multiple sclerosis 710
neuroleptic malignant syndrome 105
opioid dependence 422
overdose 769–771
pregnancy 603–608, 608, 612
rectal 301, 303
renal impairment 647, 651–653, 656
re-starting after non-adherence 795
schizophrenia negative symptoms 32, 33
serotonin reuptake inhibition 347, 347
sexual adverse effects 345–346, 344, 345
street drug interactions 451
sublingual 298, 299
INDEX

antidepressants (cont’d)
suicidality and 259
surgical patients 781, 782–783, 785
swapping/stopping 314–320, 316–319
transdermal 300–301, 302–303
antidiuretic hormone, syndrome of
inappropriate secretion see syndrome of
inappropriate antidiuretic hormone
anti-epileptics
clozapine-treated patients 176
dementia patients 561–563, 567
opiod withdrawal 420
antiparkinsonians see anticonvulsants
antihistamines
borderline personality disorder 665
dementia 565, 567, 580
see also cyproheptadine; loratadine;
pronethazine
antihypertensives
antipsychotic-related hypertension 132
treatment failure 51–52, 162–165
clinical practice 15–16
monotherapy 8, 20–22
switching 50–52, 150–152
tardive dyskinesia see tardive dyskinesia
 ventures thromboembolism 153–155
weight gain see weight gain
alcohol use disorders 403, 756
alternative views on 28–29
amfetamine psychosis 440
anorexia nervosa 667, 668
atrial fibrillation 720
atypical/typical dichotomy 3–4
bipolar disorder 226, 244
bipolar disorder 226–228, 250–251
borderline personality disorder 664
breastfeeding 620, 621, 625–626
catatonia 108–109, 109, 110
children and adolescents 524
bipolar illness 471, 472,
473–474, 475
obsessive-compulsive disorder 488
psychosis 478
PTSD 492, 493
choosing 4–6
classification 3–4, 44
combination therapy 8, 20–24, 47
rapid tranquillisation 57
treatment failure 51–52, 162,
162–165
delirium 674–675, 676
delirium tremens 389
dementia 572–575, 575, 813
depress see depot antipsychotics
depression 268, 278
discontinuation 28–29
dose-response effects 16, 49–50
doses 8
equivalent 14, 14, 15
loading 47
maintenance treatment 27
maximum licensed 12–13
minimum effective 9, 9
when to increase 49–50
driving and 777
ECT augmentation 86–87
ECT interactions 282
epilepsy 692–693
first-episode psychosis 25–26
first generation see first-generation
antipsychotics
hepatic impairment 636, 637–638, 641
high-dose 16–19
adverse effects 17
efficacy 16–17
monitoring 18
prescribing 17–18
HIV infection 680, 681
Huntington’s disease 705, 706
information for patients 28
learning disabilities 701
long-acting injections see depot
antipsychotics
maintenance treatment 25–27, 26
monitoring 8, 36, 37–38, 47
monotherapy 8, 20–22
multi-episode schizophrenia 26–27
multiple sclerosis 711
negative symptoms 31–35
neonatal discontinuation symptoms 604
neuroscience-based nomenclature
(NbN) 4, 44
NICE guidelines 46–48
non-adherence 6, 27, 109
management 40, 41, 42, 66
re-starting after 795
obsessive compulsive disorder 364
older people 588–591
overdose 771
Parkinson’s disease 716
plasma level monitoring 732–738,
733, 789
plasma level variations 50
pregnancy 602–604, 604, 612
prescribing principles 8
PRN (pro re nata) prescribing 8, 21
prophylaxis 25–30, 26
PTSD 363
rapid tranquillisation 54–56, 57–59
relative efficacy 5–6
renal impairment 647, 649–650, 656
response 49–53
second generation see second-generation
antipsychotics
smoking interactions 765–766
street drug interactions 451
surgical patients 783
switching 50–52, 150–151, 150–152
synthetic cannabinoid receptor agonist
(SCRA)-related psychosis 448
tic disorders 513–514
typical/atypical dichotomy 3–4
valproate interactions 217
antiretroviral agents
adverse psychiatric effects 686, 686
HIV-associated neurocognitive
disorders 682
interactions with drugs of abuse 450
pharmacodynamic interactions 685, 685
pharmacokinetic interactions 450, 685
antisocial personality disorder, ADHD
and 498
antispasmodics, in dementia 563, 567
anxiety 360
alcohol dependence 403
autism spectrum disorders 508
epilepsy 688
Huntington’s disease 706, 707
non-psychotropics causing 808,
809, 810
smoking 766
barbiturates  
ECT interactions 282
psychiatric side-effects 690
see also phenobarbital
bariatric surgery 722–728
antipsychotic-induced weight gain 101
drug formulations 722–723
pharmacokinetic changes 722
psychotropic prescribing after 723–727, 726
basophils 805
behavioural and psychological symptoms of dementia (BPSD) 570–585, 581
analgesics 571
antidepressants 577–578
antipsychotics 572–575, 813
benzodiazepines 373–383
benzamides, substituted 3
benperidol 389
benztropine 389
benzodiazepines 373–383
acute mania/hypomania 235, 236
adverse effects 374–375
akathisia 95, 96
alcohol withdrawal 389, 390–395, 393, 394, 403
antagonism see flumazenil
anxiety spectrum disorders 361–365, 373
anxiety with alcohol dependence 403
anxiolytic 373
bariatric surgery 726
borderline personality disorder 665
breastfeeding 629
caffeine interaction 761
catatonia/stupor 108, 109
children and adolescents
anxiety disorders 482, 482
autism spectrum disorders 506, 508
delirium 675
dementia 577
dependence (misuse) 377–380, 445–446, 446, 455
alcohol dependence with 401
pregnancy and 445–446
urine screening 377
depression 374
detoxification 377–380
discontinuation 445, 446
disinhibitory reactions 381–383
dosage reduction 378–379
driving and 777, 778
drug interactions 223, 235
ECT interactions 281
GBL and GHB withdrawal 442, 443
generalised anxiety disorder 360
HIV infection 682
Huntington’s disease 706
hypnotic 373
methadone interaction 410, 412
misuse see benzodiazepines, dependence
multiple sclerosis 709
neuroleptic malignant syndrome and 105
older people 374, 577
overdose 772
panic disorder 362
post-mortem blood concentrations 743
pregnancy 611, 612
psychiatric side-effects 690
psychosis 374
rapid tranquillisation 54, 55, 56, 374
renal impairment 655
smoking status and 750
social phobia 366
street drug interactions 452
surgical patients 783
switching to diazepam 378, 378
synthetic cannabinoid receptor agonist (SCRA) withdrawal 449
tolerance test 377–378
withdrawal symptoms 377, 377
benzotropine see benzatropine
Best Interests Meeting 594, 595–596
beta-agonists, in dementia 563
beta blockers
generalised anxiety disorder 360
multiple sclerosis 709
psychiatric adverse effects 810
PTSD in young people 492, 493
social phobia 366
see also propranolol
betahistine 100
betaxolol
bexarotene-induced constipation 195
sexual dysfunction 144, 144, 345
beverages see drinks
bexarotene, schizophrenia 162
bicarbonate, plasma 800
bilirubin, serum 800
binge eating disorder 667, 669, 670
biochemical effects, psychotropic drugs 798, 799–804
bipolar depression 243–249
alternative treatments 245
antipsychotic-induced switching 226, 230
antipsychotic therapy 226, 244
carbamazepine 221, 243, 245
children and adolescents 472–473, 474, 475
drug treatment 243–246, 244–245
lithium 206, 244, 246
meta-analysis 243
pregnancy 611
psychostimulants 286
suicide risk 243, 250
valproate 215, 244
bipolar disorder 205–253
alcohol dependence with 402–403
antipsychotics 226–228
pneumonia risk 148
atrial fibrillation and 720
children and adolescents 467, 471–477, 473–475
ADHD and 472
chronic kidney disease 647
HIV infection 681–682
lithium 205–206
mixed states 250
mood stabilisers 205–224
multiple sclerosis 710–711
older people 590–591
physical monitoring 232–233
plasma level monitoring 233, 733, 734
pregnancy and post partum 608–610, 611
prophylaxis 250–253, 251
antipsychotic long-acting injections 229, 229–231
antipsychotics 226, 250–251
carbamazepine 221–222, 250, 251
lithium 206, 250, 251
NICE guidance 250–251, 251
valproate 215, 250, 251
rapid-cycling 241, 241–242
smoking cessation 435
see also bipolar depression; mania
bisphosphonates 668
bitopertin 32, 163
bleeding, SSRi-related 293, 347–354, 348
blonanserin 162
blood drug concentrations
post-mortem 742–744, 743
see also plasma drug level monitoring
blood pressure (BP) 130–133
antidepressant-induced changes 326–327
antipsychotic-induced changes 38, 130, 156
monitoring 62
bipolar disorder 233
rapid tranquillisation 62
see also hypertension; hypotension
body dysmorphic disorder (BDD) 367
Botulinum toxin 326–327
breastfeeding 619–634
bradykinesia, antipsychotic-induced 32, 91–92, 150
breast surgery, SSRI-treated patients 622
bromocriptine 139, 424
hypnotics 621, 622–624
bupropion (amfebutamone) 299
bupropion + naltrexone 299
buprenorphine/naloxone (Suboxone) 414
buprenorphine 414–418
burexiprazole 299
brexpiprazole 305
breathalyser 387
bradycardia, anticholinesterase inhibitors and 537–538, 539
bradykinesia, antipsychotic-induced 32, 91–92, 150
breastfeeding 619–634
antidepressants 621, 622–624
antipsychotics 621, 625–626
hypnotics 621, 629
buccal
infant exposure to drugs 619
mood stabilisers 621, 627–628
opioid dependence 428
prescribing principles 619–620
sedatives 620
stimulants 630, 630
see also post-partum period
breast surgery, SSRI-treated patients 351, 351
breathalyser 387
bregiprazole adverse effects 39
blood lipids and 119
breastfeeding 625
diabetes and 125
epilepsy 693
equivalent dose 15
hepatic impairment 637
maximum licensed dose 13
minimum effective dose 9
older people 588
sexual function and 143
weight gain risk 97
British Association for Psychopharmacology (BAP) guidelines
alcohol withdrawal 390–393
bipolar disorder 206, 243, 250
dementia 534, 531, 551
lithium monitoring 206, 209
obscene compulsive disorder in young people 485–486
schizophrenia 33
bromocriptine 139, 144
bronzodilators, in dementia 563–564, 567
bupropion 299
bulimia nervosa 667, 669, 670
buprenorphine 414–418
analgesia for patients on 426
cautions 417–418
clinical effectiveness 414
detoxification regimes 422, 423, 423, 424
drug interactions 418
less than daily dosing 417
methadone vs 408, 409
older people 565
overdose 418
precipitated withdrawal 414, 416, 416
pregnancy and breastfeeding 427, 428
prescribing information 414
QT prolongation 413
refractory depression 274
re-titration after non-compliance 795
stabilisation dose 417
starting dose 414, 415
starting treatment 415
transfer from methadone to 415–417, 416
transfer from other prescribed opioids to 417
transfer to methadone from 417
wash-out period 425
HIV infection 681
Huntington’s disease 706
multiple sclerosis 709
refractory depression 267, 269, 271
renal impairment 655
sexual dysfunction 144, 144, 345
butyrophenones 3
breastfeeding 625
overdose 771
butyrylcholinesterase (BuChE) 529
cabergoline 139, 274
caffeine 759–764
consumption in mental illness 762–763
content of drinks 759, 762
interactions 760, 761
intoxication 761, 761
Parkinson’s disease 717
pharmacokinetics 760
psychotropic effects 760
calcium, plasma 800
calcium channel blockers, psychiatric adverse effects 810
Camcolt 207
Cancer 144, 145, 435
psychostimulants for depression 287
valproate therapy 214
see also chemotherapeutic agents
cannabinoids anorexia nervosa 667
Huntington’s disease 705
tic disorders 514
see also synthetic cannabinoid receptor agonists
Cannabis 448, 449, 455
drug interactions 451–452
schizophrenia negative symptoms 33
tic disorders 514
capacity, mental 818
assessment 593
camouflaging of medicines and 593–596, 597
learning disabilities 699–700
carbamazepine 221–225, 224
acute mania/hypomania 221
adverse effects 222–223, 690–691
alcohol misuse 756
bariatric surgery 725
benzodiazepine withdrawal 379
bipolar depression 221, 243, 245
bipolar disorder 221–222, 224, 280, 251
breastfeeding 627
dementia 579
discontinuation 223
Index 831
carbamazepine (cont’d)
  drug interactions 223–224, 688–690
  formulations 221
hepatic impairment 640
HIV infection 681
hyponatraemia risk 335
indications 221–222, 224
learning disabilities 701
lithium interaction 212
mechanism of action 221
older people 591
on-treatment monitoring 223, 232–233
overdose 771
plasma levels 222, 733
pregnancy 610, 611
pre-treatment tests 223
psychiatric adverse effects 690, 808
PTSD in young people 493
renal impairment 654, 656
re-starting after non-adherence 795
smoking status and 750
street drug interactions 452
surgical patients 782
women of child-bearing age 223, 601

carbohydrate-deficient transferrin (CDT) 800
cardiac arrhythmias see arrhythmias
cardiomyopathy, clozapine-induced 184–186
cardiovascular adverse effects 690, 808
cardiovascular disease
  acetylcholinesterase inhibitors 537–538, 539
  antidepressants 325–332, 326–327
  antipsychotics 112–133, 572–574
  clozapine 174, 184–188
  risk in anorexia nervosa 667–668
  cardiovascular agents 565–566
cardiovascular disease
  antidepressant prescribing 325, 326–327, 329
cigarette smokers 765, 766
clozapine and 158
  dementia 575, 577
  depression 467, 473–475
  nicotine 759
  smoking status and 750
  street drug interactions 452
  smoking; weight gain 329

children and adolescents 461–524
  ADHD 496, 496–503
  alcohol dependence 400–401
  anxiety disorders 480–484, 482, 491–494
  bipolar illness 467, 473–477, 473–475
  depression 463–470, 467
  eating disorders 669
  lithium plasma levels 207
  medication doses 524
  melatonin for insomnia 517–520, 519
  obsessive compulsive disorder 485–490, 487
  prescribing principles 461–462
  psychosis 478–479
  PTSD 484, 491–495, 493
  rapid tranquillisation 521–522, 521–523
  tics and Tourette’s syndrome 512–516, 515
  Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
    485, 487
  chloridiazepoxide
    alcohol-dependent pregnant women 400
    alcohol withdrawal 393, 393–393, 394
    diazepam equivalent dose 378
    renal impairment 655
    chloride, serum 801
    chloroquine 809
    chlorpheniramine 565
    chlorpromazine 3
    adverse effects 39
  breastfeeding 626
  dose 16, 17
  equivalent doses 14, 14
  first-episode psychosis 25
  hepatic impairment 638
  maximum licensed dose 12
  minimum effective dose 9
  monitoring physical health 37, 38
  NICE guidance 47
  overdose 771
  renal impairment 649
  sexual adverse effects 143
  smoking status and 750
  venous thromboembolism risk 153
  weight gain risk 97
  chocolate 759
  cholesterol, blood 119, 120–121, 801
  cholinesterase inhibitors see acetylcholinesterase inhibitors
  chorea, Huntington’s disease 704, 705
  chronic kidney disease 647
  see also renal impairment
  Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
  formula 645, 646
  cigarettes, electronic see electronic cigarettes
  cigarette smoking see smoking
  cimetidine
  caffeine interaction 761
  carbamazepine interaction 224
  clozapine 158
  psychiatric adverse effects 566, 811
  Cymbalta 517, 519, 815
citalopram
  adverse effects 358
  alcohol dependence 402, 756
  anxiety disorders 367
  breastfeeding 622
  cardiac effects 326, 329, 330
  children and adolescents 524
  anxiety disorders 482
  depression 464
  obsessive compulsive disorder 485
  PTSD 492, 493
dementia 577, 578
  depression 267, 267
  epilepsy 692
  hepatic impairment 639, 641
  HIV infection 680–681
  Huntington’s disease 706
  interferon-α-induced depression 681
  intravenous (IV) 298–302, 300
  minimum effective dose 262
  multiple sclerosis 710
  obsessive compulsive disorder 364
  older people 287, 587
  post-stroke depression 290, 291
  renal impairment 651, 656
  switching from 314
 hypersalivation 171, 175, 189–190, 189–192
 hypertension 131–132, 175
 hyponatraemia 134
 neutropenia and agranulocytosis 176, 179, 184–185, 197–201
 older people 525
 orthostatic hypotension 130, 175
 pneumonia 148, 180
 serious haematological and cardiovascular 184–188
 sexual dysfunction 143
 uncommon or unusual 179–180, 179–183
 weight gain 97, 175
 alternatives 162–165, 162–168
 antipsychotic polypharmacy vs 21–22
 atrial fibrillation 720
 augmentation 51–52, 158
 to ameliorate adverse effects 20, 158
 NICE guidance 47
 suggested options 159
 autism spectrum disorders 508
 bariatric surgery 724
 bipolar disorder 226, 241
 borderline personality disorder 664
 breastfeeding 621, 625
 caffeine interaction 761
 catatonia 109, 110
 chemotherapy and 202–203
 children and adolescents 478, 524
 classification as atypical 3–4
 community-based patients 170–174, 172–173
 dementia 572
 dosing/titration
 community-based patients 171, 172–173
 maximum licensed dose 12
 re-starting after a break 169, 169, 795
 starting regimen 156, 156–157
 target dose 158
 ECT augmentation 86–87
 ECT interactions 282
 epilepsy 693
 first-episode psychosis 25, 40
 fluoxetine interaction 259
 hepatic impairment 637
 HIV infection 680
 Huntington’s disease 705
 initiation schedule 156–157
 learning disabilities 701
 lithium combinations 198–199, 200, 207
 monitoring physical health 37, 38, 170–173, 173
 monotherapy 158
 multiple sclerosis 711
 negative symptoms 32
 NICE guidance 46, 47
 older people 588–589
 optimising treatment 158–161
 overdose 771
 Parkinson’s disease 716, 717
 plasma levels 733, 735–736
 acting on results 744–745, 744–745
 optimising treatment 158
 response threshold 158, 735
 post-mortem blood concentrations 743
 pregnancy 603, 604
 relapsed schizophrenia 41
 relative efficacy 5, 6
 renal impairment 649
 smoking cessation and 750, 766
 surgical patients 783
 switching to 173
 tardive dyskinesia and 92
 tic disorders 514
 treatment-resistant schizophrenia 16–17, 50, 156–203
 unlicensed use 815
 for water intoxication 134
 cocaine 439, 456
 co-existing alcohol dependence 401
 co-morbid methadone use 412
 detoxification 439
 drug interactions 451–452
 post-mortem metabolism 742, 743
 substitution treatment 439
 Cockcroft–Gault equation 645, 645
 cocoa 547
 codeine 565
 co-enzyme Q10 710
 coffee 759
 cognitive behavioural therapy (CBT)
 ADHD in adults 498
 children and adolescents
 anxiety disorders 480
 depression 463, 465, 466
 obsessive compulsive disorder 485, 486, 487–488, 489
 PTSD 491, 492
 multiple sclerosis 710
 schizophrenia 162
 see also behavioural therapies
 cognitive enhancers (anti-dementia agents) 529–543, 530–531
 adverse effects 537–539
 Alzheimer’s disease 529–543
 atrial fibrillation 720
 clinical effectiveness 532–534
 combination therapy 536
 delirium 675
 dosing 535
 drug interactions 539–540, 541–542
 Huntington’s disease 707
 Lewy body dementia 533, 538, 550
 mechanisms of action 529
 mild cognitive impairment 533, 537, 550
 multiple sclerosis 711
 NICE guidance 543, 544, 576
cognitive enhancers (anti-dementia agents) (cont'd)
non-cognitive symptoms of dementia 535, 576
other dementias 530–551
Parkinson's disease 550, 716, 717
quantifying effects 534
renal impairment 656
stopping treatment 540–543, 543
switching between 534
tolerability 536–537
vascular dementia 549
see also acetylcholinesterase (AChE) inhibitors; memantine
cognitive impairment
delirium 672, 673
HIV-associated 682
Huntington’s disease 707
mild see mild cognitive impairment
multiple sclerosis 711
non-psychotropics causing 808, 810, 811
see also dementia; learning disabilities
colitis, clozapine-induced 179
Community Treatment Order (CTO) 820
complementary therapy 371, 717
compliance see adherence, medication
compliance aids 42, 791
compliance therapy, schizophrenia 791
Concerta see methylphenidate
Concerta XL 500
conduction disturbances, antidepressant-induced 326–327, 358–359
confusion
antipsychotic-induced hyponatraemia 134
non-psychotropics causing 808, 809
post-ECT 282
Confusion Assessment Method
(CAM) 672
consent
capacity to give see capacity, mental
definition 818
duty to give information 819
to ECT 820
learning disabilities 699–700
to medication 816–818
constipation, clozapine-induced 175, 193, 193–196
contraception, bipolar illness 209,
217, 223
conversion disorder stupor 107,
108, 109
co-pharmacy, paediatric practice 461
coronary artery bypass surgery 351, 351
corticosteroids, psychiatric adverse effects 710–711, 810
covered administration of medicines 527,
593–598, 597
COX-2 inhibitors 32, 211–212
C-reactive protein (CRP) 185, 186, 800
creatinine (phospho)kinase 38, 194, 801
creatinine, serum 645, 646, 801
creatinine clearance (CrCl) 645, 645
crisis management, borderline personality disorder 665
CUtLASS trial 5, 44, 90, 142
delirium, in dementia 561, 565
D-cycloserine
childhood obsessive compulsive disorder 489
panic disorder 362
PTSD in young people 484, 494
refractory depression 274
cyproheptadine
akathisia 92, 95
sexual dysfunction 142, 144, 345
unlicensed use 815
cyproterone, tic disorders 514
cystatin C protein 645
cytochrome P450 (CYP) enzymes
acetylcholinesterase inhibitor
interactions 539–540
alcohol interactions 753, 753, 754
anticholinergic agents 561
anticonvulsant interactions 217,
223–224
antidepressant interactions 239,
321, 322
caffeine interactions 760, 761
pregnancy-related changes 601
psychotropic drug interactions 746,
746–749
smoking interactions 750
St John’s Wort interactions 356
dapoxetine 343–345
darifenacin 557, 562
darunavir 685
dehydroepiandrosterone (DHEA) 668
delirium 672–678
clozapine-induced 179
diagnostic criteria 672
GHB and GBL withdrawal 442
HIV infection 680
non-psychotropics causing 808, 809,
810, 811
prophylaxis 676
surgical patients 785
treatment 673, 674–676
delirium tremens (DTs) 389
demeclocycline 134
dementia 529–585
anticholinergic drug use 557–561
antidepressant-related risk 296
BAP guidelines 551
behavioural and psychological symptoms
see behavioural and psychological
symptoms of dementia
cognitive enhancers see cognitive enhancers
cognitive side-effects of drugs 557–566,
558–560
covered administration of medication 527,
593–598, 597
driving regulations 776
frontotemporal 530, 551
HIV-associated 682
Huntington's disease 707
learning disabilities and 689
with Lewy bodies see Lewy body dementia
mixed 549, 551
neurological causes of rare 550–551
NICE guidance 543, 544, 576
other treatments 543–549
Parkinson's disease 550, 715, 716
safe prescribing for physical conditions 557–569, 567–568
vascular 529, 549
see also Alzheimer's disease; cognitive impairment; mild cognitive impairment
depression
dependence syndrome 385–386
depot antipsychotics (long-acting injection antipsychotics) 6, 66–85
bariatric surgery 724
bipolar disorder 229, 229–231, 230
differences between 67
dose reduction 73–74
doses and frequencies 68
epilepsy 693
equivalent doses 14, 15
intramuscular anticholinergics and 69, 821
intramuscular injection sites 821–822
maintenance treatment 26–27
management of patients 73–74
maximum licensed doses 12
NICE guidance 47
non-adherent patients 791
older people 590–591
oral medication vs 69
pharmacokinetics 71, 71–72
prescribing principles 8, 66–67
test doses 66, 68
depression 255–359
22q11.2 deletion syndrome 697
adherence to medication 788
alcohol-dependent patients 402
atrial fibrillation and 720
autism spectrum disorders 508
benzodiazepines 374
bipolar see bipolar depression
caffeine consumption 762
carbamazepine 221
children and adolescents 463–470, 467
chronic kidney disease 647
dementia 577–578
diabetes and 340–341
ECT see under electroconvulsive therapy
epilepsy 688
first episode 306
drinks
caffeine content 759, 762
coffeine drug interactions 281–282, 281–284
refractory depression 271
schizophrenia 86–87, 163
electroencephalography (EEG) 38
electrolyte disturbances 668, 756
electronic cigarettes (vaping) 765
adverse effects 436, 766
aiding smoking cessation 435–436, 437
Elvane see lisdexamfetamine
elevitagravir 686
elevitagravir/cobicistat 685
efratibat 685, 686
energy drinks 759, 762
eflurane 781
etacapone 810
eosinophilia, drug-induced 179, 805
epilepsy 688–695
divating 691
learning disability 700
psychiatric co-morbidities 688, 689
psychotropic-induced seizures 691, 692–693
psychotropic prescribing 688, 692–693
see also anticonvulsants; seizures
Eplim Chrono 214
EFS see extrapyramidal symptoms
Equasym see methylphenidate
Equasym XL 500
erectile dysfunction 144, 145, 345
erothyroside sedimentation rate (ESR) 805
erythromycin, drug interactions 224,
375, 527
estradiol, in schizophrenia 163
eszopiclon, drug interactions 655
ethanol see alcohol
ethosuximide 690, 808
ethyl-eicosapentaenoic acid 705
evramine 686
euphoria, non-psychotropics causing
358
adverse effects 358
alcohol dependence 402
breastfeeding 622
cardiac effects 326
children and adolescents 482
breastfeeding 622
diabetes mellitus and 340
eating disorders 669
ECT interactions 281
epilepsy 692
hepatic impairment 639
HIV infection 681
hyperprolactinaemia and 337
hyponatraemia 333
minimum effective dose 262
multiple sclerosis 710
obssesive compulsive disorder 364
elderly people 294, 295, 587
overdose 770
Parkinson's disease 715
post-mortem blood concentrations 743
post-stroke depression 290
pregnancy 607
PTSD 363
renal impairment 651
sexual adverse effects 344
smoking status and 751
switching to/from 317–319
DVLA see Driver and Vehicle Licensing
Agency
dyslipidaemia
antipsychotic-related 119–122
pseudoephedrine 134
screening 120
switching antipsychotics 150
treatment 120–121
see also lipids, blood
dysphoria
antipsychotic-induced 44
non-psychotropic-induced 808, 810
dysthymia 256, 257
dystonia
after rapid tranquillisation 55, 62
antipsychotic-induced 91–92
Huntington's disease 705
never-medicated schizophrenia 90
switching antipsychotics 150
EAGLES study 434
early-onset schizophrenia-spectrum (EOSS)
disorder 478
eating disorders 667–671
ataxial 669
Ebstein's anomaly 609
eCG see electrocardiography
ecochoradiography, clozapine-treated
patients 185
e-cigarettes see electronic cigarettes
ectasy 451–452
ECT see electroconvulsive therapy
eflamoxen 685, 686, 686
eicosapentaenoic acid (EPA)
depression 275
schizophrenia 88, 159
ejaculation, premature 343–345
elderly see older people
electrocardiography (ECG)
acetycholinesesterase inhibitor-treated
patients 538
anorexia nervosa 667–668
antidepressant-treated patients 329,
330–331
antipsychotic-treated patients 37, 46,
112–116
bipolar disorder 209, 233
methadone-treated patients 412–413,
413
QT interval measurement 112, 113
rapid tranquillisation 61
electroconvulsive therapy (ECT)
antidepressant prophylaxis after 307
catatonia 86, 108, 109
children and adolescents 465
dementia 580
epilepsy 691
legal aspects 819–820
multiple sclerosis 710
Parkinson's disease 715
pregnancy 608
psychotic depression 279
psychotropic drug interactions 281–282,
hepatotoxicity
drug-induced 641–642
valproate-induced 216
herbal medicines
hyperprolactinaemia 139
schizophrenia 165
see also Ginseng; ginseng; St John’s wort
heroin 456
drug interactions 451–452
substitution see opioid substitution
treatment
wash-out period 425
withdrawal 407–408
see also opioid dependence
high-density lipoprotein (HDL) 119, 802
HIV-associated neurocognitive disorders (HAND) 682
HIV infection/AIDS 679–687
adverse effects of antiretrovirals 686, 868
drug misusers 450
pharmacodynamic interactions 685, 685
pharmacokinetic interactions 679
psychostimulants 287
psychotropic prescribing 679–684
risk factors for psychiatric symptoms 679
homocysteine 544
Hospital Order 816
5-HT, agonists, psychiatric adverse effects 808
5-HT, antagonists
akathisia 92, 95
sexual dysfunction 142
5-HT, antagonists 364, 563
see also Granisetron; ondansetron
5-HT, receptor antagonists 547
human immunodeficiency virus see HIV
Huntington’s disease (HD) 704, 704–708
cognitive symptoms 707
mental and behavioural symptoms 704–705, 706–707
motor symptoms 704, 705
huperzine A, Alzheimer’s disease 545–546
9-hydroxyrisperidone see paliperidone
hydroxyzine 360, 565
hyoscine (scopolamine)
adverse effects in dementia 563, 564
clozapine-induced hypersalivation 175, 190
depression 274, 302
hypercalcaemia, lithium-induced 208
hyperemesis gravidarum 602, 611
hyperperforatum see St John’s wort
hyperlipidaemia see dyslipidaemia
hyperparathyroidism, lithium-induced 208
hyperprolactinaemia
antidepressants and 337, 337–339
antipsychotic-induced 39, 44, 137,
137–140, 604
management 138, 139, 139
monitoring 38, 233
other causes 137
sexual dysfunction 137, 142
switching antipsychotics 150
hypersalivation
clozapine-induced 171, 175, 189–190, 189–192
management in dementia 564
hypersomnia, depression with 286
hypertension
antipsychotic-induced 110–112
clozapine-induced 175
hypertriglyceridaemia 119, 120
hypokalaemia–related QTc prolongation 115
hypokinetic rigidity, Huntington’s disease 705
hypomania 235–240
children and adolescents 471–472
treatment 235, 235–240
see also mania
hypoglycaemia, alcohol-induced 756
hypoalbuminaemia 95
hospitalised drug misusers 447–448
hypokalaemia 137, 142
hypomania 235–240
hypopituitarism 139
hypothyroidism, lithium-induced 208
ibuprofen 282
idazoxan 547
illicit drugs see ‘street drugs’
liopenidone
adverse effects 39
bipolar disorder 226
blood lipid changes 119
blood pressure effects 130
breastfeeding 626
equivalent dose 15
hepatic impairment 637
maximum licensed dose 13
minimum effective dose 9
neuroleptic malignant syndrome 105
older people 589
overdose 771
weight gain risk 97
imipramine
adverse effects 358
children and adolescents 464–465, 492, 493
discontinuation symptoms 311
generalised anxiety disorder 361
hyperprolactinaemia 337
panic disorder 362
PTSD 363, 492, 493
rectal 301, 303
renal impairment 652
sexual adverse effects 344
transdermal (nanoemulsion) 301, 303
impaired glucose tolerance
antipsychotic-related 123–129
switching antipsychotics 150
impulsiveness, autism spectrum disorders 305–306
inattention, autism spectrum disorders 305–306
indinavir 685
indometacin 564
infants, breastfed 619, 620, 622–630
injecting rooms 419
insulin 245, 362
insomnia see sleep disturbances/insomnia
insulin-like growth factor 1 (IGF-1) 505
insulin resistance 123, 124
interferon-α 681, 811
interferon-β 709, 819
International Classification of Diseases 10 (ICD-10) 385, 497
International Normalised Ratio (INR) 807
Intestinal Obstruction, clozapine-induced 179
intestinal obstruction, clozapine-associated 194
intoxication, acute
buprenorphine risks 418
caffeine 761, 761
methadone risks 418
rapid tranquillisation 56
'street drugs' 450
synthetic cannabinoid receptor agonists (SCRAs) 447–448, 448
see also alcohol intoxication; overdose
intracranial haemorrhage (ICH), SSRI-induced 349, 350
intramuscular injection sites 821–822, 821–823
Index

Ipratropium 190, 563–564
Irritability
  autism spectrum disorders 506–508
  Huntington’s disease 706, 707
Learning disability 701
Non-psychotropics causing 808, 809, 810
Isocarboxazid 359, 795
Isoniazid 566
Isotretinoin 811
K2 (synthetic cannabinoid) 447
Ketamine
  abuse 456
  acute behavioural disturbance 56–57
  bipolar depression 245
  children and adolescents 489
  depression 271, 302
  drug interactions 451–452
  obsessive compulsive disorder 365, 489
  psychotic depression 279
  PTSD 363
Ketanserin, tic disorders 514
Ketoconazole, depression 772
Ketamine
  eating disorders 669
  renal impairment 286
  PTSD 363
  pregnancy 609, 611
  prescribing 210
  pre-treatment tests 209, 210
  re-starting after non-adherence 207
  surgical patients 784, 785
  toxicity 208
  unipolar depression 206–207, 307
  lithium carbonate tablets 207
  lithium citrate liquid 207
  liver disease
    buprenorphine cautions 417
    drug-induced 641–642
    prescribing principles 635–636
  liver function tests (LFTs) 635
  bipolar disorder 232
  carbamazepine and 222
  clozapine-induced changes 179
  drug-induced hepatotoxicity 642
  schizophrenia 38
  valproate and 216
  loxetine
    adverse effects 358
    cardiac effects 326, 329, 330
    minimum effective dose 262
    overdose 294, 587
    re-starting after non-adherence 795

Laxatives
  clozapine-induced constipation 194–195
  dementia 561, 567
  learning disabilities (LD) 699–703
  assessment of care environments 700
  capacity and consent 699–700
  medications used 701–702
  physical co-morbidity 700
  psychological interventions 700
  sensitivity to side-effects 700
  leucopenia, psychotropics causing 806
  levetiracetam
    acute mania 237
    alcohol dependence 400
    bipolar disorder 241
    Huntington’s disease 705
    psychiatric adverse effects 690, 809
    social phobia 366
    tic disorders 514
    levodopa 705, 716, 809
    levomepromazine 12, 573
    levomilnacipran
      adverse effects 344, 358
      minimum effective dose 262
    levothyroxine see thyroxine
    Lewy body dementia 550
    acetylcholinesterase inhibitors 538, 550, 576, 717
    clinical practice guidance 551
    libido (sexual desire) 141
    effects of antidepressants 344
    reduced 142, 144, 343
    licensed medicines, unlicensed use see off-label prescribing
    lifestyle interventions 99, 123
    lipids, blood
      antipsychotic drug effects 119–122
      monitoring 37, 120, 121, 232
      see also dyslipidaemia
    alpha-lipoic acid 100
    lipo-proteins, plasma 802
    liraglutide 100, 126
    lisdexamfetamine
      ADHD 497, 499, 500
      autism spectrum disorders 506
      binge eating disorder 669
      breastfeeding 630
      depression 286
      lithium 205–213
      acute mania/hypomania 205, 213, 236
      adverse effects 208
      alcohol dependence 402, 756
      autism spectrum disorders 508
      bariatric surgery 725
      bipolar depression 206, 244, 246
      bipolar disorder 205–206, 250, 251
      borderline personality disorder 664–665
      breastfeeding 621, 628
    caffeine interaction 761
    children and adolescents 472, 473, 524
    clozapine-treated patients 198–199, 200, 207
    compliance 206, 209
    discontinuation 209–210
    driving and 777
    drug interactions 210, 210–212, 224
    ECT interactions 282
    epilepsy 692
    formulations 207
    hepatic impairment 640, 641
    HIV infection 681
    Huntington’s disease 706
    for hyponatraemia 134
    indications 205–207, 210
    learning disabilities 702
    mechanism of action 205
    multiple sclerosis 711
    neuroleptic malignant syndrome 105
    neuroprotective effects 205
    older people 591
    on-treatment monitoring 209, 210, 232–233
    overdose (acute) 772
    plasma levels 207, 733
    post-mortem blood concentrations 743
    pregnancy 609, 611
    psychological interventions 99, 123
    re-starting after non-compliance 210
    re-titration after non-compliance 794–795, 795
    schizophrenia 32, 164
    surgical patients 782
    luteinizing hormone, pathological (PLC) 710
    lavender oil 361
    lactate dehydrogenase
Index

lobexidine 190, 424
long-acting injection (LAI) antipsychotics see depot antipsychotics
loop diuretics, lithium interaction 211
lorperamide
opioid withdrawal 420
safety in dementia 561, 567
lopinavir 681, 685
loratadine 345, 563
lorazepam
acuta mania/hypomania 236
alcohol withdrawal 393
breastfeeding
rapid tranquillisation 55, 56, 57
children and adolescents 482, 521
delirium 675
diazepam equivalent dose 378
driving and 778
hepatic impairment 641
HIV infection 682
older people 592
rational tranquillisation 53, 56, 60
children and adolescents 521
intramuscular injection site 821
renal impairment 655, 656
lormetazepam 378
low-density lipoprotein (LDL) 119, 802
loxapine
adverse effects 39
autism spectrum disorders 508
children and adolescents 522
diabetes risk 123
epilepsy 693
rapid tranquillisation 54, 60, 522
smoking status and 751
LSD (lysergic acid diethylamide) 456
luxiprostine 194–195
lurasidone
adverse effects 39
atrial fibrillation 720
bariatric surgery 724
bipolar depression 243, 244
bipolar disorder 226, 251
blood lipids and 119
blood pressure effects 130
breastfeeding 625
children and adolescents 474, 475
diabetes and 125, 126
dose escalation 50
epilepsy 693
equivalent dose 15
hepatic impairment 637
maximum licensed dose 12
minimum effective dose 9
older people 589
overdose 771
QT prolongation 114
reversible schizophrenia 163
renal impairment 649
sexual adverse effects 143
switching to 99
weight gain risk 97
lymphocytes 805
lysergic acid diethylamide (LSD) 456
MAIN-AD study 576
mania
acute 235–240
antipsychotics 226–227, 235, 236
carbamazepine 221
lithium 205–206, 235, 236
NICE guidelines 215
other treatments 237
patients on long-term lithium 206
treatment 235, 235–240, 236
valproate 214–216, 235, 236
children and adolescents 467, 471–472, 473–474, 475
HIV infection 681–682
multiple sclerosis 710–711
non-psychotics causing 809, 810, 811
unplanned pregnancy 217, 223
MAOIs see monoamine oxidase inhibitors
maprotiline 692
mavogluarant 705
Moxepa see omega-3 fatty acids
MDA (3,4-methylenedioxyamfetamine) 451–452
MDRD (Modification of Diet in Renal Disease) formula 645, 646
mean cell haemoglobin 806
mean cell haemoglobin concentration 806
mean cell volume 806
mebeverine 420, 563
mecamylamine 274
medical illness
antidepressant delivery methods 298–303, 299–301
catatonia-like states 107–108
learning disability 700
safe prescribing in dementia 557–569, 567–568
secondary depression 287, 293
medication
adherence see adherence, medication
assessing attitudes to 789
covert administration in food or drink 527, 593–598, 597
legal framework 816–820
paying patients to take 593
refusal to take 593
re-starting after non-adherence 794–797, 795
Medicines and Healthcare Products Regulatory Agency (MHRA)
antipsychotic-induced weight gain 101
amoxapine 703,
benzodiazepine withdrawal 379
childhood insomnia 517–520, 519, 524
delirium 676
older people 592
prolonged-release formulations 517
sleep disturbances in dementia 579–580
unlicensed use 815, 815
see also agomelatine
MEMAGE study 536
memantine 530–531
acute mania 237
adverse effects 538–539
Alzheimer’s disease 529, 533–534, 535, 540–543
clinical guidelines 544, 551, 551
combination therapy 536
dementia with Lewy bodies 550
drug interactions 542
efficacy 532, 533–534
extended release 535
mechanism of action 529
multiple sclerosis 711
non-cognitive symptoms of dementia 576
obscene compulsive disorder 364
Parkinson’s disease 717
renal impairment 656
re-starting after non-adherence 795
schizophrenia 32, 159, 163
stopping treatment 540–543
switching to/from 534
tolerability 537
vascular dementia 549
menstrual disorders, SSRI-associated 350
mental capacity see capacity, mental
Mental Capacity Act (MCA) 593, 594, 595, 818
Mental Health Act (MHA) 593, 595, 816–820
capacity 818
civil and forensic detention 816–817
community patients 820
completing forms T2 and T3 817
definition of consent 818
ECT 819–820
section 62 urgent treatment 819
section 132 duty to give information 819
SOAD visits 817
statutory consultees 817–818
melatonin
antipsychotic-induced weight gain 101
amoxapine 703,
mental illness
22q11.2 deletion syndrome 696, 697
alcohol use disorders 401–403
caffeine consumption 762–763
driving and 777
illicit drug use 454
learning disabilities 699
nicotine use 765–766
metabolic inducers 746–749
metabolic inhibitors 116, 158, 746–749
metformin
antipsychotic-induced weight gain 99–101, 100
hyperprolactinaemia 139, 139
methadone 408–413, 456
acute in-patient settings 421
anaesthesia for patients on 426
bariatric surgery 726
buprenorphine vs 408, 409
cautions 412
clinical effectiveness 408–410
detoxification regimes 422, 423
driving regulations 776
drug interactions 223, 410, 412, 451–452
induction and stabilisation in community 411–412
information for patients 410
initial total daily dose 411
overdose/toxicity 410–411, 412, 772
post-mortem blood concentrations 743
pregnancy and breastfeeding 427, 428
prescribing information 410–411
QT prolongation/ECG monitoring 412–413, 413
re-titration after non-compliance 795
surgical patients 784
transfer from buprenorphine to 417
transfer to buprenorphine from 415–417, 416
wash-out period 425
withdrawal 408
methamphetamine, misuse 439–440
methylcellulose 101
methyl dopa 697
methylphenidate
22q11.2 deletion syndrome 697
ADHD 500
adult 498, 498, 499
childhood 496, 496
alcohol interaction 733
autism spectrum disorders 505–506
bariatric surgery 726
breastfeeding 630
depression 285, 286–287
driving and 777
epilepsy 693
hepatic impairment 640
learning disabilities 702
modified-release preparations 500
psychotic depression 279
re-starting after non-adherence 795
unlicensed use 815
metoclopramide
adverse effects 96, 105
alcohol withdrawal 396
clozapine-induced hypersalivation 190
dementia patients 561
opiod withdrawal 420
tic disorders 514
metyrosine 697
MHRA see Medicines and Healthcare products Regulatory Agency
mianserin
adverse effects 358
akathisia 92, 95
breastfeeding 623
overdose 770
post-stroke depression 290
refractory depression 268
schizophrenia 32, 163
midazolam
akathisia 96
children and adolescents 521, 522
rapid tranquilisation 54, 55, 56, 60
midodrine 131
mifepristone 245, 279
mild cognitive impairment (MCI) 550
BAP guidance 551, 551
cognitive enhancers 533, 537, 550
vitamin supplements 544
mineral supplements, anorexia nervosa 668
Mini Mental State Examination (MMSE) 532, 540
minocycline
psychotic depression 279
schizophrenia 32, 163
mirtazapine
adverse effects 358
akathisia 92, 95
alcohol dependence 402
bariatric surgery 723
breastfeeding 623
cardiac effects 325, 326, 329
children and adolescents
anxiety disorders 482, 482
depression 465
depression 264
diabetes mellitus and 340
discontinuation symptoms 310
driving ability 777
ECT interactions 281
epilepsy 692
generalised anxiety disorder 361
hepatic impairment 639
HIV infection 681
Huntington's disease 706, 707
hyperprolactinaemia and 337
intravenous 300, 302
methylphenidate with 287
minimum effective dose 262
multiple sclerosis 710
obsessive compulsive disorder 364
older people 295, 587
overdose 770
panic disorder 362
post-mortem blood concentrations 743
post-stroke depression 290
pregnancy 608
PTSD 363
refractory depression 267, 268, 269
renal impairment 652
schizophrenia 32, 163
sexual adverse effects 344
sexual dysfunction therapy 142–144, 345
smoking status and 751
switching to/from 314, 316–317, 319
missed doses, re-starting medication after 794–795, 795
moclobemide
adverse effects 359
bipolar depression 245
breastfeeding 623
cardiac effects 327, 329, 330
clozapine-induced hypersalivation 190
epilepsy 692
hepatic impairment 639
minimum effective dose 262
multiple sclerosis 710
overdose 770
panic disorder 362
pregnancy 607
renal impairment 652
sexual adverse effects 344
social phobia 366
surgical patients 782
switching to/from 316–317, 319
modafinil
ADHD 497
antipsychotic-induced weight gain 101
bipolar depression 245
cocaine misuse 439
depression 285, 286, 287
multiple sclerosis 711–712
overdose 772
refractory depression 274
schizophrenia 32
surgical patients 784
Modification of Diet in Renal Disease (MDRD) formula 645, 646
molidone 13, 15
monoamine oxidase inhibitors (MAOIs)
adverse effects 238, 359
alcohol interactions 756
breastfeeding 623
caffeine interaction 761
carbamazepine therapy and 224
cardiac effects 326
depression 258, 274
diabetes mellitus and 340, 341
discontinuation 311, 312, 318
drug interactions 323
ECT interactions 281
epilepsy 692
generalised anxiety disorder 361
hepatic impairment 639
HIV infection 681
Huntington’s disease 706
hyperprolactinaemia and 337
hypnotics 333, 333
overdose 770
panic disorder 362
pregnancy 608
PTSD 363
re-starting after non-adherence 795
sexual adverse effects 344
surgical patients 781, 782
switching to/from 316, 318
monocytes 806
Montgomery–Asberg Depression Rating Scale (MADRS) 265
Montgomery versus Lanarkshire Health Board appeal case 813
mood disorders see affective disorders
mood stabilisers 205–225
acute mania/hypomania 235, 233–236, 236
alcohol misusers 756
atrial fibrillation 720
autism spectrum disorders 508
bariatric surgery 725
biochemical side-effects 799, 802, 803
bipolar depression 244, 286
bipolar disorder 205–225
children and adolescents 471–472, 473
prophylaxis 250–251
rapid-cycling 241
borderline personality disorder 664–665
breastfeeding 620, 621, 627–628
chronic kidney disease 647
dementia 579
hepatic impairment 640, 641
HIV infection 681
multiple sclerosis 711
older people 591–592
overdose 771–772
pregnancy 609–610, 611, 612
PTSD in young people 493
renal impairment 654, 656
street drug interactions 452
see also anticonvulsants; carbamazepine; lithium; valproate
morphine
obsessive compulsive disorder 365
older people 365
PTSD prevention 494
slow release oral (SROM), opioid dependence 418
movement disorders, nicotine use 766
multiple sclerosis (MS) 709–714, 710
multivitamins see vitamin supplements
music therapy 571
mutism, akinetic see catatonia
myasthenia gravis 564, 567
myocardial infarction (MI) 325
antidepressant prescribing after 325, 326–327, 329
antipsychotic-associated 154
protective effects of SSRIs 325, 349
myocarditis, clozapine-induced 174, 184–186, 186
myoclonus 176, 705
nabumetone 705
N-acetylcycteine see acetylcysteine
nalinefemone 398
naloxone
buprenorphine overdose 418
opioid overdose 405, 406
take-home 421
naloxone/buprenorphine (Suboxone) 418, 427
naltrexone
alcohol dependence 397–398, 398, 401
co-morbid mental illness 402–403
amphetamine misuse 440
analgesia for patients on 398, 426
antipsychotic-induced weight gain 101
borderline personality disorder 665
learning disabilities 702
opiod dependence 424–425, 425
re-starting after non-adherence 795
unlicensed use 815
naproxen 564
Naranjo adverse drug reaction probability scale 811, 812
National Institute for Health and Clinical Excellence (NICE)
adherence to medication 789, 790
adult ADHD 497, 498
alcohol misuse 387, 397, 397, 398, 399, 399, 400
anxiety spectrum disorders 365, 368–369, 373
bipolar depression 243
bipolar disorder 215, 250–251
pregnancy 609, 611
prophylaxis 251
borderline personality disorder 663–664, 665
care home residents 596
children and adolescents
ADHD 496
anxiety disorders 480
bipolar illness 471
depression 463, 467
obsessive-compulsive disorder 486, 487, 487, 489
PTSD 491
dementia 543, 544, 576
depression 256, 278, 307
eating disorders 670
lipid-lowering guidance 120–121
opioid dependence 408, 422
pregnancy 604
schizophrenia 4, 46–48
smoking cessation 431
National Poisons Information Service (NPIIS) 442
nausea/vomiting
antidepressant-induced 358–359
clozapine-induced 176
see also anti-emetics
nelﬁnivir 685
neﬁmitide 274
neonatal abstinence syndrome (NAS) 427–428
neonates
antidepressant discontinuation symptoms 606, 607, 608
antidepressant-treated mothers 605, 606–608
antipsychotic discontinuation symptoms 604
antipsychotic-treated mothers 602, 603
breastfed 619, 620, 622–630
opioid-dependent mothers 427–428
persistent pulmonary hypertension of 607
see also breastfeeding
neostigmine 564, 567
NEURAPRO trial 88
‘neuroleptic equivalence’ 14
neuroleptic malignant syndrome (NMS) 104–106
diagnosis and management 104
renal impairment 647
vs catatonic stupor 108, 109
neuroleptics see antipsychotics
neurological causes of rare dementias 550–551
neuroscience-based nomenclature (NhN) 4, 44
neurotoxicity, lithium 208
neuropenia
benign ethnic 197, 198, 200
benzamazepine-induced 222, 224
chemotherapy-associated 202
clozapine-induced 176, 179, 197–201
psychotropics causing 806
see also agranulocytosis
neutrophils 806
nevirapine 681, 686
NICE see National Institute for Health and Clinical Excellence
nictine 765–768
dependence 431–438
psychotropics effects 765
tic disorders 514
withdrawal symptoms 767
see also smoking; smoking cessation
nicotine replacement therapy (NRT) 431–433
adverse effects 432–433
combination 431–432, 436, 437
e-cigarettes 435, 437
preparations and dose 432
nimodipine, bipolar disorder 241
nizatidine 378, 655
nortriptyline 101
NMS see neuroleptic malignant syndrome
nocturnal enuresis, clozapine-induced 176
non-adherence see adherence
non-psychotropic drugs
psychiatric adverse effects 808, 808–811
QT prolongation 115
non-steroidal anti-inflammatory drugs (NSAIDs)
dementia 548, 564
lithium interactions 210, 211–212
SSRI combination 348, 348, 350
nortriptyline 158, 736
obesity see bariatric surgery; weight gain
Objective Opioid Withdrawal Scale (OOWS) 407, 408
obsessive compulsive disorder (OCD) 364–365, 367
22q11.2 deletion syndrome 697
children and adolescents 485–490, 487
Huntington’s disease 706, 707
NICE guidance 369, 486, 487, 487, 489
obstetrical haemorrhage, SSRl-induced 350
ocular pigmentation, clozapine-induced 179
oculogyric spasm (crisis) 62, 91
oestrogens
anorexia nervosa 668
caffeine interaction 761
carbamazepine interactions 223
depression 275
schizophrenia 163
off-label prescribing 813–815
pediatric practice 461, 486, 488, 492
Royal College consensus statement 814, 814
olanzapine
acute mania/hypomania 226–227, 235, 236
adverse effect profile 39
amlatamine psychosis 440
anorexia nervosa 667, 668
atypical antipsychotics 720
bariatric surgery 724
bipolar disorder 243, 244, 246
bipolar disorder 226, 241, 250
borderline personality disorder 664
breastfeeding 625
catatonia 109, 110
children and adolescents 524
autism spectrum disorders 508
bipolar mania 473, 475
psychosis 478
PTSD 492
rapid tranquillisation 521
classification 4
delirium 674, 676
dementia 572, 573, 574, 575
diabetes association 124
dyslipidaemia risk 119–120
epilepsy 693
first-episode psychosis 25
fluoxetine combination see olanzapine + fluoxetine
hepatic impairment 637
Huntington’s disease 705, 706
hypertension risk 132
hypnopatarea 134
learning disabilities 701
long-acting injection (LAI) (mainly pamoate) 67, 77–78
doses and intervals 68, 77
intramuscular injection site 821
pharmacokinetics 71
post-injection syndrome 77–78
switching 77
maximum licensed dose 12
multiple sclerosis 711
older people 589
opioid-dependent patients 422
overdose 771
Parkinson’s disease 716
plasma levels 50, 733, 736
pneumonia risk 148
post-mortem blood concentrations 743
pregnancy 603, 604
psychotic depression 278
PTSD 363
rapid tranquillisation 54, 55, 56, 60
intramuscular injection site 821
renal impairment 649, 656
schizophrenia
acute exacerbation or relapse 41
clozapine augmentation 159
dose escalation 16–17, 49
equivalent dose 15
maintenance therapy 27
minimum effective dose 9
monitoring physical health 37
refractory 162, 163–164
relative efficacy 5, 6
switching to 51, 95
treatment failure 51
sexual adverse effects 143
smoking status and 751
social phobia 366
therapeutic index 44
tic disorders 514
valproate interaction 217
for water intoxication 134
weight gain risk 97
olanzapine + fluoxetine (Symbyax) bipolar depression 243, 244, 246
children and adolescents 472, 474, 475
psychotic depression 278
refractory depression 268
older people 525–598
alcohol dependence 401
anticholinergic agents 557–564, 561, 567, 568
benzodiazepines 374
cognitive adverse effects of drugs 357–366, 558–560
covit administration of medication 527, 593–598, 597
delirium 672, 673
depression 293–297, 294–295
antidepressant doses 587–588
maintenance therapy 306, 307
psycho stimulant 287
drug interactions 211, 526–527
hypnotics 592
medication doses 587–592
pharmacodynamic changes 525
pharmacokinetic changes 526
prescribing principles 525–528, 527
renal impairment 646
see also dementia
Omacor see omega-3 fatty acids
omega-3 fatty acids (fish oils)
Alzheimer’s disease 545
bipolar depression 245
child and adolescent depression 465
multiple sclerosis 710
refractory depression 275
schizophrenia 88–89, 159, 164
ondansetron
obsessive compulsive disorder 364
schizophrenia 32, 164
tic disorders 314
opioid analogues
dementia 565, 571
methadone/buprenorphine-treated patients 409, 426
naltrexone-treated patients 398
opioid-dependent pregnant women 427–428
psychiatric adverse effects 808
surgical patients 781
osteoporosis 668, 691
osteopenia 323
overactivity, autism spectrum disorders 505–506
overdose, psychotropic drug 769–772, 769–775
oxazepam
alcohol withdrawal 393
breafasting 629
diazepam equivalent dose 378
oxcarbazepine
adverse effects 691
bipolar disorder 222, 237
child and adolescent bipolar illness 473
dementia 579
drug interactions 690
mechanism of action 221
psychiatric side-effects 690
oxybutynin
clozapine-induced hypersalivation 190
HIV infection 682
oral interference 655
pain management
dementia 571
opioid-dependent patients 409, 426
paliperidone
adverse effects 39
alcohol misusers 756
atrial fibrillation 720
bipolar disorder 229
breafasting 626
children and adolescents 478
equivalent doses 80
hepatic impairment 638, 641
hypotension 771
hypoponeraemia 134
maximum licensed dose 12
monitoring physical health 38
neuroleptic malignant syndrome 105
overdose 771
palmitate long-acting injection (LAI) 67, 79–81
1-monthly 68, 79, 79
3-monthly 68, 81, 81
dose equivalents 80, 82
dose reduction 73
equivalent dose 15
intramuscular injection site 821, 822
maximum licensed dose 12
older people 590, 591
pharmacokinetics 71
switching to 80
vs haloperidol decanoate 45, 79
plasma level monitoring 733, 738
renal impairment 650
sexual adverse effects 143
weight gain risk 97
palliative care, substance misusers 426
pancreatitis 120, 179, 800
PANDAS 514–515
panic disorder 362, 365, 367
NICE guidance 368
non-psychotropics causing 808, 809
PANS (Paediatric Acute-onset Neuropsychiatric Syndrome) 514–515
paracetamol, in dementia 564, 571
paroxetine
antipsychotic-induced 39, 91–92
never-medicated schizophrenia 90
switching antipsychotics 150
valproate-induced 216
see also extrapyramidal symptoms
Parkinson’s disease 715–718
beta-agonist bronchodilators 563
cognitive enhancers 550, 551, 717
dementia 550, 715, 716
depression 715
psychiatric adverse effects of medications 809–810
psychosis 716, 716–717
smoking 766
parotid gland swelling, clozapine-induced 179
paroxetine
adverse effects 258, 358
alcohol dependence 403
anxiety disorders 367
atrial fibrillation 720
breastfeeding 623
cardiac effects 327
children and adolescents
anxiety disorders 481, 482
depression 464
obsessive compulsive disorder 485
discontinuation symptoms 311, 312
drug interactions 259, 321
hepatic impairment 639, 641
HIV-associated neurocognitive disorders 682
Huntington’s disease 706
hyperprolactinaemia and 337
minimum effective dose 262
multiple sclerosis 710
obsessive compulsive disorder 367
older people 294
post-stroke depression 291
pregnancy 606–607
renal impairment 653
Index 847

anticonvulsants 610, 611, 612
antidepressants 605–608, 608, 612
antipsychotics 602–604, 604, 612
anxiety disorders and
insomnia 611–612
bipolar illness 608–610, 611
depression 604–608, 608
discussions with women 600
mood stabilisers 609–610, 611, 612
opioid dependence 409, 427–428
prescribing principles 601
psychosis 600–604
psychotropic drug choice 599–600, 612
sedatives 611–612, 612
unplanned 217, 223
see also breastfeeding; women of child-bearing age
pregnenolone, schizophrenia 32
Prescribing Observatory for Mental Health (POMH-UK) 21
Priadel 207
priapism 142, 143
pridopidine 705
primidone 690, 690, 691
problem behaviours see behaviour problems
prochlorperazine
alcohol withdrawal 396
opioid withdrawal 420
venous thromboembolism risk 153
procyclidine 62, 69
Product Licence (PL), prescribing drugs outside 813–815
prolactin, serum
antipsychotic drug effects 137, 137
elevated see hyperprolactinaemia interpretation 137, 138
monitoring 38, 233
psychotropics affecting 803
promazine 39
promethazine
borderline personality disorder 665
breastfeeding 629
cognitive adverse effects 565
dementia 580
pregnancy 602, 601, 612
rapid tranquillisation 54–55, 60–61
children and adolescents 522
intramuscular injection site 821
renal impairment 655
street drug intoxication 450
propantheline 190
propentofylline 164
propofol, GBL and GHB withdrawal 443
propranolol
akathisia 92, 95
autism spectrum disorders 508
generalised anxiety disorder 360
lithium-induced tremor 208
psychiatric adverse effects 810
PTSD in young people 492, 493, 494
protein, serum 803
prothrombin time 807
proton pump inhibitors 176, 566
pseudocholinergic affect (PBA), multiple sclerosis 710
pseudohypothyroidism 134
pseudo-parkinsonism see parkinsonism
psychiatric adverse effects
anticonvulsants 688, 690, 808–809
antiretroviral drugs 686, 686
dementia 557–566
differential diagnosis 811, 812
non-psychotropic drugs 808, 808–811
psychiatric disorders see mental illness
psychological therapies
anxiety disorders 368
children and adolescents
ADHD 496
anxiety disorders 480, 483–484
bipolar disorder 472
depression 463
PTSD 494
psychosis 255
learning disabilities 700
see also cognitive behavioural therapy
psychosis
alcohol consumption and 755
amfetamine 440
benzodiazepines 374
children and adolescents 478–479
ECT 86–87
epilepsy 688
first episode see first-episode psychosis
Huntington’s disease 706, 707
multiple sclerosis 711
non-psychotropics causing 808, 809, 810, 811
older people 588–590
Parkinson’s disease 716, 716–717
post-partum 600–604
pregnant women 600–604
rapid tranquillisation see rapid tranquillisation
sexual dysfunction 141–142
super-sensitivity 28–29
synthetic cannabinoid receptor agonist (SCRA)-related 448–449
see also schizophrenia
psychosocial treatment, drug dependence 405, 419, 439,
445, 449
psychostimulants see stimulants
psychotic depression 278–279
psychotropic medications
adverse reactions see adverse drug reactions
after bariatric surgery 723–727, 726
atrial fibrillation 719, 720
biochemical effects 798, 799–804
breastfeeding 619–630, 620
child and adolescent doses 524
cytchrome function and 746, 746–749
driving and 776–780, 777
ECT interactions 281–282, 281–284
epilepsy 688–691, 692–693
haematological effects 798, 805–807
HIV infection 685, 685
off-label prescribing 813–815
overdose 769–772, 769–775
pharmacodynamic interactions see pharmacodynamic interactions
pharmacokinetic interactions plasma level monitoring 731–741
pregnant women 599–613, 601, 612
smoking status and 750–751, 750–752,
766–767
street drug interactions 450–453,
451–452
surgery and 781–786, 792–784
PTSD see post-traumatic stress disorder
publication bias 814
pulmonary embolism, antipsychotic-associated 154, 184
pulmonary hypertension of newborn, persistent 607
pulse monitoring 62, 171
pure red cell aplasia 807
pyridostigmine 564, 567
pyridoxine (vitamin B6) 96
QT interval 112
corrected (QTc) 112, 413
measurements 112, 113
QT prolongation 112–118
anorexia nervosa 667
antidepressant-induced 326–327, 329
newborn 606
antipsychotic-induced 112–116
ECG monitoring 114
management 116
metabolic inhibition 116
quantifying risk 113, 114
rapid tranquillisation 55–56, 57
switching agents 150
methadone therapy 412–413, 413
non-psychotropics inducing 115
renal impairment and 647
risk factors 114, 115
see also arrhythmias
quetiapine
acute mania/hypomania 235, 236
adverse effect profile 39
anorexia nervosa 667, 668
bariatric surgery 724
bipolar disorder 226, 241, 243, 250
blood lipids and 119
blood pressure effects 130
breastfeeding 626
quetiapine (cont'd)

children and adolescents 524

autism spectrum disorders 508

bipolar illness 472, 474, 475

psychosis 478

PTSD 492, 493
clozapine-induced hypersalivation 190
delirium 675
dementia 572, 573, 574, 575
depression 244

psychotic 278

refractory 206, 268
diabetes association 124

epilepsy 693
equivalent dose 15
generalised anxiety disorder 360

hepatic impairment 638

HIV infection 680

Huntington's disease 706

hypertension risk 131, 132

hypomania 134

learning disabilities 701

maximum licensed dose 12

older people 589

overdose 771

Parkinson's disease 716

plasma level monitoring 733, 736–737

post-mortem blood concentrations 743

pregnancy 603, 604

PTSD 363

rapid tranquillisation 60

renal impairment 650

schizophrenia

combination therapy 21

high dose 16–17, 49

minimum effective dose 9

monitoring physical health 38

multi-episode 27

refractory 164

relative efficacy 5

switching to 51, 95

sexual adverse effects 143

synthetic cannabinoid receptor agonist (SCRA) withdrawal 449
tardive dyskinesia and 92
tic disorders 514

for water intoxication 134

weight gain risk 97

raloxifene 164

raltegravir 685, 686

ranitidine 100, 366

rapid neuroleptisation 47

rapid tranquillisation (RT) 54–59, 60–61

benzodiazepines 54, 55, 56, 374

children and adolescents 521–522, 521–523, 478

intramuscular treatment 54–56, 60, 821

intravenous treatment 54–55, 56, 60

ketamine 56–57

oral treatment 54, 60

paradoxical disinhibitory reactions 382

physical monitoring 61

practical measures 57–59

pregnancy 612

remedial measures 62

zuclopenthixol acetate 57–59, 59

reboxetine

adverse effects 358

antipsychotic-induced weight gain 101

breastfeeding 624

cardiac effects 327

diabetes mellitus 340

epilepsy 692

hepatic impairment 639

HIV infection 681

hyperprolactinaemia and 337

minimum effective dose 262

older people 295

overdose 770

post-stroke depression 290

pregnancy 607

renal impairment 653

sexual adverse effects 344

switching to/from 316–317, 319

Red Bull 759

red cell count 807

red cell distribution width 807

refusal of medication 593

Regional Drugs and Therapeutics Centre Teratology Service 400

relative infant dose (RID) 619, 622–630

renal function testing 645

antipsychotic-treated patients 37

lithium-treated patients 209, 232

older people 526

renal impairment 645–660

anti-dementia medications 656

antidepressants 651–653, 656

antipsychotics 649–650, 656

anxiolytics and hypnotics 655, 656

classification 646

lithium and 208, 654

methadone dosing 412

mood stabilisers 654, 656

prescribing principles 645–647

recommended drugs 656

renal replacement therapy 647

Research Units on Paediatric Psychopharmacology (RUPP) Autism Network 505–506

respiratory depression 62, 373

Responsible Clinician (RC) 816

restlessness see akathisia

restricted repetitive behaviours and interests (RRBs) 504–505

Restriction Order 816

reticuloocyte count 807

Rett's syndrome 504

reversible inhibitors of monoamine oxidase-A (RIMA) see moclobemide

rhabdomyolysis 647

rilpivirine 685, 686

riluzole

bipolar depression 245

children and adolescents 489

generalised anxiety disorder 361

Huntington's disease 705

obsessive compulsive disorder 365, 489

refractory depression 275

schizophrenia 164

risperidone

acute mania/hypomania 226–227, 235, 236

ADHD 497

adverse effect profile 39, 82

bariatric surgery 724

bipolar disorder 226, 241, 250

blood lipids and 119, 120

breastfeeding 626

catatonia 109, 110

children and adolescents 524

autism spectrum disorders 505, 506–507, 507, 508

bipolar illness 473, 475

psychosis 478

PTSD 492, 493

classification 4

delirium 675

dementia 572, 573, 574, 575

depression 271

diabetes association 124

epilepsy 692

first-episode psychosis 25

hepatic impairment 638

HIV infection 680

Huntington's disease 705, 706

hypertension risk 131, 132

hypomania 134

learning disabilities 701

long-acting injection (RLAI) 67, 82–85

bipolar disorder 229, 229, 230

dose equivalents 80, 82

dose-response effects 82

doses and intervals 68

equivalent dose 15

intramuscular injection site 821

maximum licensed dose 12

neuroleptic malignant syndrome 105

new formulations 84

older people 591

pharmacokinetics 71

plasma levels 82, 737

refractory schizophrenia 164

switching from 75

switching to 83

maximum licensed dose 12

multiple sclerosis 711

older people 589

overdose 771

Parkinson's disease 716

plasma levels 50, 733, 737–738
post-mortem blood concentrations 743
pregnancy 603, 604
PTSD 363
rapid tranquillisation 60
renal impairment 650
schizophrenia
acute exacerbation or relapse 41
equivalent doses 15, 80
high dose 16–17, 49–50
maintenance therapy 27
minimum effective dose 9
monitoring physical health 38
refractory 159, 162, 164
relative efficacy 5
switching to 51
treatment failure 51
sexual adverse effects 143
tic disorders 513–514
for water intoxication 134
weight gain risk 97
RISQ-PATH study 113
Ritalin 500
see also methylphenidate
ritanserin 164, 237
ritonavir 450, 685
rivastigmine 530–531
adverse effects 537–538
Alzheimer’s disease 532, 533, 535, 540–543
atrial fibrillation 720
delirium 675, 676
drug interactions 540, 541
efficacy 532, 533
HIV-associated neurocognitive disorders 682
mechanism of action 529
NICE guidance 544
non-cognitive symptoms of dementia 576
renal impairment 656
stopping treatment 540–543
tolerability 536–537
dermal patch 533, 536–537
vascular dementia 549
rofecoxib, mild cognitive impairment 550
Roux-en-Y gastric bypass (RYGB) 722
Royal College of Psychiatrists, unlicensed use of licensed drugs 814, 814
RT see rapid tranquillisation
S-adenosyl-L-methionine 275
safron 546
saquinavir 685
sarcosine 164
schizoaffective disorder
atrial fibrillation and 720
ECT 86
schizophrenia 3–203
22q11.2 deletion syndrome 696, 697
acute exacerbation 41–42, 52
alcohol dependence with 403
antipsychotic therapy see antipsychotics
atrial fibrillation and 720
benzodiazepines 374
caffeine consumption 762
carbamazepine 222
cardiovascular risk factors 119
catastic 107, 108–109, 109, 110
children and adolescents 478–479
chronic kidney disease 647
diabetes association 123
driving regulations 777
ECT 86–87
first episode see first-episode psychosis
HIV infection 680
medication adherence 27, 787–788, 790
enhancing 4, 791–792
monitoring physical health 8, 36, 37–38, 47
mortality 20
multi-episode 9, 26, 26–27
negative symptoms 31–35
NICE guidelines 4, 46–48
older people 588–590
omega-3 fatty acids 88–89
pneumonia 148
pregnancy and 602
refractory see schizophrenia, treatment resistant
relapse 26–27, 28
alternative views 28–29
treatment algorithms 41–42
sexual dysfunction 141
smoking 765–766
cessation 432, 435, 766
substance misuse 454
treatment algorithms 40–42, 40–43
treatment resistant (TRS) 5, 49–52, 156–203
alternatives to clozapine 162–165, 162–168
dose escalation 16–17, 49–50
ECT 86–87, 163
treatment options 50–52
see also clozapine
valproate therapy 165, 215
water intoxication 134
see also antipsychotics
scopolamine see hyoscine
second-generation antipsychotics (SGAs) 4, 44
ADHD 497
adverse effects 90
diabetes 123–125, 126
dyslipidaemia 119–120
extrapyramidal symptoms 90
neuroleptic malignant syndrome 105
orthostatic hypotension 130
psychosis 148
sexual dysfunction 142
weight gain 97, 97–98
bipolar disorder 226, 250
children and adolescents
autism spectrum disorders 505, 506–508, 507
bipolar illness 471–472, 473–474
psychosis 478
PTSD 492, 493
delirium 674–675
dementia 572–575
equivalemt doses 15
HIV infection 680
Huntington’s disease 705, 706
learning disabilities 701
long-acting injections
bipolar disorder 230
intramuscular injection sites 821–822
schizophrenia 66–67, 75–85
maximum licensed doses 12, 13
minimum effective doses 9
negative symptoms 32
NICE guidelines 46
older people 588–589, 590–591
pregnancy 603–604
rapid tranquillisation 54
relative efficacy 5–6
renal impairment 649–650
social phobia 366
street drug interactions 451
switching trials . 51
tic disorders 513–514
unlicensed use 815
second opinion appointed doctor (SOAD) 817, 819
sedation
alcohol-induced 755
antidepressant-induced 294–295, 358–359
antipsychotic-induced 39
clozapine-induced 171, 175
driving ability and 778
high dose 56
non-psychotropics causing 808, 809, 810
switching antipsychotics 150
see also rapid tranquillisation
sedatives
antipsychotics as 8
borderline personality disorder 663, 665
breastfeeding mothers 620, 620
hepatic impairment 641
opioid-dependent patients 422
pregnancy 611–612, 612
seizures
22q11.2 deletion syndrome 697
alcohol withdrawal 389
antidepressant-induced 322
clozapine-induced 176, 735
melatonin-treated children 518
psychotropics-associated, in epilepsy 691, 692–693
see also epilepsy
selective serotonin reuptake inhibitors (SSRIs)
22q11.2 deletion syndrome 697
adverse effects 258, 358
children and adolescents 465, 467, 481, 483, 486
older people 525
alcohol misuse 756
anxiety disorders 365–367
atrial fibrillation 720
bariatric surgery 723
bleeding risks 293, 347–354, 664
caffeine interaction 761
cardiac effects 325, 451
children and adolescents 465, 482, 483
anxiety spectrum disorders 505, 506, 508
behavioural activation response 467
depression 463–464, 465–467, 476
obeseptive compulsive disorder 485–486, 488
PTSD 492, 493
dementia 577–578
depression 258
adjunctive stimulants 286, 287
bipolar 244, 246
minimum effective doses 262
NICE guidance 256
older people 294, 298
post-stroke 290, 291
refractory 206, 268, 271, 275
diabetes mellitus and 340, 341
discontinuation symptoms 311
drug interactions 259, 323, 688–690
eating disorders 669
ECT interactions 281
epilepsy 692
generalised anxiety disorder 360
hepatic impairment 639
HIV infection 680–681, 682
Huntington’s disease 706, 707
hyperprolactinaemia and 337
hypomania 333, 333, 334
learning disabilities 701
lithium interactions 212
multiple sclerosis 710, 710
neuroleptic malignant syndrome and 105
obsessive compulsive disorder 364, 367
older people 294, 294
opiod-dependent patients 422
overdose 770
panic disorder 362
Parkinson’s disease 715
post-mortem blood concentrations 743
pregnancy 605, 606–607, 608
PTSD 363
re-starting after non-adherence 795
serotonin reuptake inhibition 347, 347
sexual adverse effects 344
social phobia 366
street drug interactions 451
surgical patients 351, 351, 781, 782
switching to/from 315, 316–319
selectine adverse effects 144–145, 810
buccal 298, 299
discontinuation 318
schizophrenia 32
SSRI interaction 715
switching to/from 316, 318
transdermal 301, 303
self-injurious behaviour (SIB)
autism spectrum disorders 506–508
learning disabilities 701–702
lithium therapy 207
serumagastat 548
semi-sodium valproate 214
acute mania/hypomania 236
see also valproate
senna 194
D-serine, schizophrenia 32, 163
serotonin-noradrenaline reuptake inhibitors (SNRIs)
adverse effects 358
anxiety disorders 365–367
bariatric surgery 723
children and adolescents 481–482, 482
diabetes mellitus and 340, 341
drug interactions 323
generalised anxiety disorder 360
HIV infection 681
Huntington’s disease 706
hyperprolactinaemia and 337
hypomania 333
multiple sclerosis 710
obsessive compulsive disorder 364
Parkinson’s disease 715
refractory depression 268
switching to/from 317–319
see also desvenlafaxine; duloxetine;
venlafaxine
serotonin syndrome 315
antidepressant-related risk 315, 322
caffeine-SSRI interactions 761
post-ECT 282
renal impairment 647, 651, 653
St John’s wort 336
surgery-related risk 781, 782, 783
sertindole adverse effects 39
breastfeeding 626
maximum licensed dose 12
minimum effective dose 9
monitoring physical health 37
schizophrenia 159, 164
weight gain risk 97
sertraline adverse effects 258, 358
alcohol misuse 402, 756
anxiety disorders 367
breastfeeding 624
cardiac effects 327, 329, 330
children and adolescents 524
depression 481, 482
obeseptive compulsive disorder 485
PTSD 492, 493
dementia 578
depression 267
children and adolescents 464
minimum effective dose 262
post-stroke 290
diabetes mellitus and 340
discontinuation symptoms 312
hepatic impairment 639, 641
Huntington’s disease 706
hyperprolactinaemia 337
multiple sclerosis 710, 710
obseseptive compulsive disorder 364, 485
older people 588
opioid-dependent patients 422
Parkinson’s disease 715
pregnancy 606, 607
rectal 301, 303
renal impairment 653, 656
social phobia 366
street drug interactions 451
unlicensed use 815
severe impairment battery (SIB) 533
Severity of Alcohol Dependence Questionnaire (SADQ) 388
sexual arousal 141
disorders 142, 144
effects of antidepressants 344
sexual desire see libido
sexual disinhibition, mania 217, 223
sexual dysfunction 141–147
antidepressants and 343–346, 344, 345, 358–359
antipsychotic-related 44, 142, 143
depression 343
effects of psychosis 141–142
hyperprolactinaemia and 137, 142
schizophrenia 141
switching antipsychotics 150
treatment 142–145, 144, 345
sexual response, human 141, 141
Short Alcohol Withdrawal Scale (SAWS) 390, 392
Shprintzen syndrome (22q11.2 deletion syndrome) 696, 696–698, 697
SIADH see syndrome of inappropriate antidiuretic hormone
sialorrhoea see hypersalivation
sildenafil 144, 145, 345
simvastatin 565
skin reactions, clozapine 180
sleep disturbances/insomnia 508, 518
dementia 579–580
non-psychotropics causing 808, 809, 810
older people 592, 567
pregnancy 611–612
see also hypnotics
alcohol dependence and 401
caffeine interaction 761
clozapine therapy and 158
drug interactions 750–751, 750–752,
766–767
pregnant women with psychiatric illness 601
schizophrenia 765–766
see also nicotine
smoking (cigarette) 743–438, 765–768
alcohol dependence and 401
caffeine interaction 761
clozapine therapy and 158
drug interactions 750–751, 750–752,
766–767
pregnant women with psychiatric illness 601
schizophrenia 765–766
see also nicotine
smoking cessation 431–438
bupropion 434, 434–435, 437
cigarette 435–436, 437
NICE guidance 431
nicotine replacement therapy 431–433,
432, 436
serious mental illness 437
surgical patients 781
treatment algorithms 436–437
varenicline 433, 433–434, 436, 437
Snoezelen 571
SNRIs see selective serotonin reuptake inhibitors
SOAD (second opinion appointed doctor) 817, 819
social and communication impairment 505
social phobia (social anxiety disorder) 366, 367
childhood 480
sodium, serum 134, 334, 803
see also hyponatraemia
sodium oxybate 669
sodium valproate 214
acute mania/hypomania 236
controlled release 214
see also valproate
SOHO trial 27
solanezumab 548–549
solifenacin 557, 562
Souvenaid 547
Spice 447
SSRIs see selective serotonin reuptake inhibitors
STAR*D programme 260, 267,
267–269, 343
statins
antipsychotic-treated patients 120–121
dementia treatment 546–547, 549
psychiatric adverse effects 810
safety in dementia 565, 567
statutory consultants 817–818
STEP-BD study 251
steroid-induced psychosis 207
steroids (corticosteroids), psychiatric adverse effects 710–711, 810
stimulants (psychostimulants) 22q11.2 deletion syndrome 697
ADHD 496–497, 498–499, 500–501
breastfeeding 630, 630
depression 285–289, 286–287
epilepsy 683
hepatic impairment 640
misuse/dependence 439–441
refractory depression 275
re-starting after non-adherence 795
see also amphetamines; atomoxetine;
methylphenidate
St John’s wort (SJW) 355–357
children and adolescents 465
drug interactions 356–357, 685
patient information 356
street drugs’ acute intoxication 56, 450
psychotropic drug interactions 450–453,
451–452
urine testing 454, 455–456
see also drug misuse/dependence
stroke antipsychotic-associated 154, 572–574
depression after 287, 290–292
SSRI-related haemorrhagic 349, 350
stupor, psychiatric 107–109, 110
stuttering, clozapine-related 180
Suboxone 418, 427
substance misuse 385–457
ADHD and 498
extrapyramidal symptoms and 90
pain management and 426
polydrug abuse 440
Subutex see buprenorphine
sudden cardiac death
antipsychotic-associated 112, 113
cardiovascular risk factors 116
clozapine-related 185
risk in depression 329
see also QT prolongation
suicide/suicidal ideation
anticonvulsants and 216, 223
antidepressants and 259
antidepressant-treated young people 465, 466–467, 486
bipolar disorder 243, 250
epilepsy 688
lithium and 207
medication adherence and 788
multiple sclerosis 709
non-psychotropics causing 809, 810, 811
paradigmatic obsession 486
perinatal 600
psychotic depression 279
psychotropic overdose 769, 769–772
schizophrenia 26
surgical patients 785
sulforaphane 505
sulpiride 4
adverse effects 39
alcohol misusers 756
breastfeeding 626
clozapine augmentation 159
clozapine-induced hypersalivation 190
diabetes risk 124
epilepsy 692
equivalent dose 14
hepatic impairment 638, 641
hypertension risk 131
maximum licensed dose 12
minimum effective dose 9
monitoring physical health 37, 38
refractory schizophrenia 164
renal impairment 650
re-starting after non-adherence 795
sexual adverse effects 143
tic disorders 514
weight gain risk 97
sumatriptan, intranasal 282
Summary of Product Characteristics (SPC) 794
super-sensitivity psychosis 28–29
surgery
psychotropic drugs and 781–786,
782–784
SSR-related bleeding 351, 351
Symbyax see olanzapine + fluoxetine
sympathetic acetylcholinesterase inhibitors and 537–538, 519
syndrome of inappropriate antidiuretic hormone (SIADH)
antidepressant-induced 333
antipsychotic-induced 134
medications associated with 800, 801
treatment 135
synthetic cannabinoid receptor agonists (SCRAs) 447–449, 455
acute intoxication 447–448, 448
dependence and withdrawal 449
related psychosis 448
see also cannabinoids
T2 and T3, forms 816–817
T3 see triiodothyronine
tachycardia, clozapine-induced 186
110
tadalafil 237
237
taladafil 144, 345
tamoxifen
antidepressant interactions 259, 321
mania 237
tamsulosin 561
tardive dyskinesia (TD) 91–92
depot antipsychotics 73
first vs second-generation antipsychotics 45
switching antipsychotics 151
treatment 92
TCAs see tricyclic antidepressants
tea 759
telmisartan 132
temazepam
diazepam equivalent dose 378
  driving and 778
  hepatic impairment 641
  HIV infection 682
  renal impairment 655
  temperature, increased body see fever
  tenofovir 685
  teratogenicity
  antidepresants 605, 606–608
  antipsychotics 602, 603
  benzodiazepines 611
  carbamazepine 223, 610
  lithium 209, 609
  topiramate 610
  valproate 217, 610
  terazosin 189
testosterone
  HIV infection 681
  psychotropic drug effects 803
  refractory depression 275
  schizophrenia 32
  sexual dysfunction 145, 345
tetrahydrocannabinol (THC) 447
  theophylline
dementia 563–564
  drug interactions 223, 259
  therapeutic drug monitoring see plasma
drug level monitoring
  thiamine
  alcohol withdrawal 393, 395–396
  deficiency 395–396
  post-ECT confusion 282
  thiazide diuretics, lithium interaction 210, 211
  thioridazine 4, 153
  thioxanthines 3
  breastfeeding 626
  sexual adverse effects 143
  thrombocytopenia, psychotropics
  causing 180, 807
  thromboembolism
  antipsychotic-associated 153–155, 154
  clozapine-associated 180, 184
  thyroid function tests (TFTs)
  bipolar disorder 208, 209, 232
  psychotropic drugs affecting 803–804
  quetiapine-treated patients 38
  thyroid-stimulating hormone 803
  thyroxine 804
  bipolar depression 245
  bipolar disorder 241
  carbamazepine interaction 223
  clozapine augmentation 159
  tiagabine 690, 809
  tianeptine, refractory depression 274
tic disorders 512–516, 515
  obsessive compulsive disorder with 488
  Timothy syndrome 1: 606
tipranavir 685
  TMS see transcranial magnetic stimulation
tolbutamide 557, 562
  tolvaptan 134
topiramate
  alcohol dependence 400
  antipsychotic-induced weight gain 101
  bipolar disorder 241
  breastfeeding 628
  cocaine misuse 439
  dementia 579
  drug interactions 690
  eating disorders 669
  mania 237
  obsessive compulsive disorder 364
  pregnancy 610
  psychiatric adverse effects 690, 809
  schizophrenia 32, 159, 164
  social phobia 366
  tic disorders 514
  TORDIA (Treatment of Resistant Depression in Adolescence) studies 463, 466, 467
torsade de pointes (TDP)
antipsychotic-induced 112, 113, 412–413
  see also QT prolongation
  torklipil
  touch, therapeutic 571
  Tourette’s syndrome 512–516, 515
  transcranial direct current stimulation (tDCS) 32
  transcranial magnetic stimulation (TMS)
  bipolar disorder in young people 472–473
  schizophrenia 32, 165
  transferrin, carbohydrate-deficient 800
  tranylcypromine
  adverse effects 359
  bipolar depression 245
  discontinuation 311, 312, 318
  overdose 770
  refractory depression 267, 268
  re-starting after non-adherence 795
  switching to/from 316, 318
  trauma exposure, preventive interventions 494
  trauma-focused cognitive behavioural therapy (TF-CBT) 491, 492
  trazodone
  adverse effects 358
  akathisia 92, 96
  breastfeeding 624
  cardiac effects 327, 329
  delirium 676
  dementia 548, 577–578, 580
  diabetes mellitus 340
  driving ability 777
  epilepsy 692
  erectile dysfunction 345
  HIV infection 681
  intravenous 300
  minimum effective dose 262
  older people 588
  overdose 770
  pregnancy 608
  rectal 301, 303
  renal impairment 653
  sexual adverse effects 344
  smoking status and 751
  switching to/from 317–319
  Treatment of Adolescents with Depression Study (TADS) 463, 465
  Treatment of Early Age Mania (TEAM) study 473
  Treatment of Resistant Depression in Adolescence (TORDIA) studies 463, 466, 467
  TREC studies 34–53
  tremor
  antipsychotic-induced 91–92
  lithium-induced 208
  valproate-induced 216
  tricyclic antidepressants (TCAs)
  adverse effects 258, 358
  alcohol dependence 402, 756
  atrial fibrillation 720
  bariatric surgery 723
  breastfeeding 624
  cardiotoxicity 327, 329, 330
  children and adolescents 464–465
  ADHD 497
  PTSD 492, 493
  dementia 578
  depression 258
  adjunctive stimulants 286
  minimum effective dose 262
  psychotic 278
  refractory 274, 275
  diabetes mellitus and 340, 341
  discontinuation symptoms 311
  drug interactions 259, 321–322
  ECT interactions 281
  epilepsy 692
  generalised anxiety disorder 361
  hepatic impairment 639
  HIV infection 681
  Huntington’s disease 706
  hyperprolactinaemia and 337
  hypomania 333
  multiple sclerosis 710, 710
  older people 294
  opioid-dependent patients 422
  overdose 770
Index 853

panic disorder 362
Parkinson's disease 715
post-mortem blood concentrations 743
pregnancy 606
re-starting after non-adherence 795
sexual adverse effects 344
smoking status and 751
switching to/from 317–319
trifluoperazine adverse effects 39
triglycerides, plasma 119, 269, 267, 271
triptorelin, obsessive-compulsive disorder 365
troponin, clozapine-treated patients 185, 186
tryptophan depletion, acute mania 237
re-fractory depression 274
22q11.2 deletion syndrome 696, 696–698, 697
urinary incontinence, anticholinergic agents 557–561, 562, 568
urinary retention, alpha blockers for 561, 568
vaginal nerve stimulation 255
vaginal bleeding, abnormal 350
valbenazine 92
valproate 214–220, 218
acute mania/hypomania 214–215, 235, 236
adverse effects 216, 690–691
alcohol dependence 402, 756
autism spectrum disorders 508
bipolar disorder 215, 244
bipolar disease 214–215, 250, 251
breastfeeding 628
children and adolescents 524
autism spectrum disorders 508
PTSD 493
controlled release 214
delirium 676
dementia 573, 579
discontinuation 217
drug interactions 217, 746
formulations 214
HIV infection 681
indications 214–215, 218
learning disabilities 701
mechanism of action 214
neuroleptic malignant syndrome 105
older people 592
on-treatment monitoring 216, 218, 232–233
overdose 772
panic disorder 362
plasma levels 215–216, 269, 271
re-fractory depression 274
re-starting after non-adherence 795
schizophrenia 165, 215
social phobia 366
street drug interactions 452
surgical patients 782
unlicensed use 815
women of childbearing age 217, 601
venlafaxine adverse effects 358
sexually transmitted 344
surgical patients 782
switching to/from 317–319
see also desvenlafaxine
venous thromboembolism 344
violent behaviour 54–64
venlafaxine adverse effects 258, 358
atypical antipsychotics 3–4, 44
see also first-generation antipsychotics
vortioxetine (cont’d)
diabetes mellitus 340
discontinuation 310, 312
epilepsy 692
generalised anxiety disorder 361
hyperprolactinaemia and 337
hyponatraemia 333
minimum effective dose 262
older people 294, 588
overdose 771
post-stroke depression 290
renal impairment 653
sexual adverse effects 344
switching to/from 317–319
warfarin
carbamazepine interactions 223
SSRIs and 348, 348–349
valproate interaction 217
water intoxication 134, 135
weight gain
anticonvulsant-induced 690
antidepressant-induced 294–295, 340
antipsychotic-induced 39, 97–103
dyslipidaemia risk 119
hypertension risk 130–131
relative risk 97, 97
switching agents 99, 151
treatment 99–103, 100–101
young people 471, 473, 474
clozapine-induced 175
psychotropic-associated, after bariatric
surgery 726
valproate-induced 216
weight monitoring
antipsychotic-treated patients 37, 99
bipolar disorder 233
children and adolescents 471, 472
renal impairment 647
Wernicke’s encephalopathy 395–396, 396
white cell count (WCC) 198–199, 200
see also neutropenia
women of child-bearing age
carbamazepine therapy 223
lithium therapy 209
prescribing principles 601
valproate therapy 217
see also breastfeeding; pregnancy;
teratogenicity
yohimbine 144, 144, 345
yokukansan 165
young people see children and adolescents
zaleplon 629, 777
zidovudine 685, 686
zinc 274, 710
ziprasidone adverse effects 39
bariatric surgery 724
bipolar disorder 226
blood lipid changes 119, 120
breastfeeding 626
catatonia 109, 110
children and adolescents 474
autism spectrum disorders 508
psychosis 478
rapid tranquillisation 522
delirium 675
depression 274
diabetes and 124–125, 126
epilepsy 692
equivalent dose 15
hypertension risk 131
mania 237
maximum licensed dose 13
neuroleptic malignant syndrome 105
overdose 771
Parkinson’s disease 716
pregnancy 604
rapid tranquillisation 54, 522
renal impairment 650
schizophrenia

dose–response effects 16, 49
minimum effective dose 9
monitoring physical health 37
refractory 159, 165
relative efficacy 5
switching to 51, 99
tic disorders 514
weight gain risk 97
zolmitriptan, akathisia 96
zolpidem
breastfeeding 629
carbamazepine interaction 223
catatonia/stupor 108
disinhibitory reactions 381
driving ability and 777
older people 592
overdose 772
post-mortem blood concentrations 743
pregnancy 612
renal impairment 655
zonisamide
alcohol dependence 400
antipsychotic-induced weight gain 101
bipolar depression 245
eating disorders 669
psychiatric adverse effects 690, 809
zopiclone
breastfeeding 629
driving ability and 777
hepatic impairment 641
older people 592
opioid withdrawal 420
overdose 772
renal impairment 655, 656
zotepine 165, 693
zuclopenthixol acetate, rapid tranquillisation 57–59, 59
adverse effects 39
breastfeeding 626
dementia 573
depot 67, 68
equivalent dose 14
intradumal injection site 821
maximum licensed dose 12
pharmacokinetics 71
equivalent dose 14
hepatic impairment 637
learning disabilities 701
maximum licensed dose 12
older people 590
renal impairment 650
smoking status and 751